Galectin Therapeutics Inc (GALT)
NASDAQ:GALT
Want to see GALT full AI Analyst Report?
GALT Stock Chart & Stats
$5.71
-$0.06(-5.00%)
At close: 4:00 PM EST
$5.71
-$0.06(-5.00%)
Day’s Range― - ―
52-Week Range$1.27 - $7.13
Previous CloseN/A
Volume135.57K
Average Volume (3M)341.94K
Market Cap
$159.37M
Enterprise Value$287.56M
Total Cash (Recent Filing)$14.11M
Total Debt (Recent Filing)$135.71M
Price to Earnings (P/E)―
Beta0.77
Next Earnings
Aug 17, 2026EPS Estimate
-0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.41
Shares Outstanding65,856,895
10 Day Avg. Volume287,288
30 Day Avg. Volume341,945
Financial Highlights & Ratios
PEG Ratio0.23
Price to Book (P/B)-2.11
Price to Sales (P/S)0.00
P/FCF Ratio-11.13
Enterprise Value/Market Cap1.80
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-23.96K
Enterprise Value/Ebitda-14.64
Forecast
1Y Price Target
$11.00Price Target Upside92.64% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.31
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Board Clinical Expertise (Dr. Henry Brem)Adding Dr. Henry Brem increases durable governance and clinical-development capability. His track record in translational medicine and regulatory navigation can materially strengthen trial design, investigator relationships and credibility with regulators and partners across multi-year late-stage programs.
Improving Cash Burn TrendSustained reduction in cash burn reflects improved cost control and operational efficiency versus prior year. This improvement lengthens runway and reduces near-term financing pressure, making it easier to advance clinical programs over the next several quarters while seeking partnerships or capital.
Focused Galectin-3 Therapeutic FranchiseA clear, differentiated mechanistic focus on galectin-3 addresses large, structural unmet needs (fibrosis, NASH, oncology). This concentrated scientific thesis supports durable IP depth, potential multi-indication development, and strategic partnering/licensing optionality across therapeutic areas.
Bears Say
No Product RevenueAs a clinical-stage biotech with no product sales, the company lacks operating cash generation. That structural revenue gap forces ongoing reliance on external financing until regulatory approval and commercialization, increasing dilution and execution risk across the multi-year development timeline.
Deeply Negative Equity And High DebtA balance sheet with deeply negative equity and sizable debt materially constrains financial flexibility. High leverage limits borrowing capacity, raises covenant and refinancing risk, and increases the likelihood of dilutive financings or urgent asset sales if clinical costs or timelines slip.
Sustained Cash Burn And Financing DependenceOngoing negative operating and free cash flow creates persistent funding needs. Reliance on equity or other external financing can dilute shareholders and constrain long-term program choices; funding availability will heavily influence timelines and the ability to complete late-stage studies.
Galectin Therapeutics News
GALT FAQ
What was Galectin Therapeutics Inc’s price range in the past 12 months?
Galectin Therapeutics Inc lowest stock price was $1.27 and its highest was $7.13 in the past 12 months.
What is Galectin Therapeutics Inc’s market cap?
Galectin Therapeutics Inc’s market cap is $159.37M.
When is Galectin Therapeutics Inc’s upcoming earnings report date?
Galectin Therapeutics Inc’s upcoming earnings report date is Aug 17, 2026 which is in 74 days.
How were Galectin Therapeutics Inc’s earnings last quarter?
Galectin Therapeutics Inc released its earnings results on May 15, 2026. The company reported -$0.08 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.08.
Is Galectin Therapeutics Inc overvalued?
According to Wall Street analysts Galectin Therapeutics Inc’s price is currently Undervalued.
Does Galectin Therapeutics Inc pay dividends?
Galectin Therapeutics Inc does not currently pay dividends.
What is Galectin Therapeutics Inc’s EPS estimate?
Galectin Therapeutics Inc’s EPS estimate is -0.09.
How many shares outstanding does Galectin Therapeutics Inc have?
Galectin Therapeutics Inc has 65,856,895 shares outstanding.
What happened to Galectin Therapeutics Inc’s price movement after its last earnings report?
Galectin Therapeutics Inc reported an EPS of -$0.08 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -7.66%.
Which hedge fund is a major shareholder of Galectin Therapeutics Inc?
Currently, no hedge funds are holding shares in GALT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Galectin Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$11.00 (92.64% Upside)
$11.00 (92.64% Upside)
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 1.0%
Last 30 Days ▼ 1.0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
87.59%
12-Months-Change
Fundamentals
Return on Equity
21.05%
Trailing 12-Months
Asset Growth
65.40%
Trailing 12-Months
Company Description
Galectin Therapeutics Inc
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer. It also engages in developing GM-CT-01, which is in pre-clinical development stage for the treatment of cardiac and vascular fibrosis, as well as focuses on developing belapectin for the treatment of psoriasis, and lung and kidney fibrosis. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.
GALT Stock 12 Month Forecast
Average Price Target
$11.00
▲(92.64% Upside)
Technical Analysis
Omeros
―
Voyager Therapeutics
―
Tectonic Therapeutic
―
Jade Biosciences
―
Tenaya Therapeutics
―
Ownership Overview
27.62% Insiders
3.82% Mutual Funds
4.52% Other Institutional Investors
60.79% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---